scioDiscover - Drug Target Discovery

 

You have identified a compound with the desired effect ?

You are looking for its targets ?

Which additional pathways are affected ?

Which proteins are altered in a diseased tissue ?

Get a complete picture of protein expression in multiple pathways !

 

In-depth knowledge about protein expression levels is crucial for the discovery and evaluation of new drug targets. Our Scio-Discover service is fully immuno-based and covers proteins involved in key disease and signaling pathways as well as secreted proteins. Only minimal sample amounts are required for highly parallel protein analysis. There is no need for sample fractionation or depletion. Our platform is capable of processing most biological samples without extensive sample preparation, saving valuable time and resources.

 

Applications

  • Drug target identification and verification studies
  • Mechanistic studies for various indications
  • Correlation of next-gen sequencing (NGS) data with protein expression levels
  • Profile cytokine and inflammatory status of your samples

 

Key Advantages

  • Low sample consumption, for example*
    • Plasma sample: 5µl
    • Tissue: 1mg (fresh-frozen)
    • Cells: 100,000
    • CSF: 5µl
  • Investigation of human, murine and rat samples**
  • Fast turnaround time, as little as two weeks***
  • No need for laborious sample depletion or fractionation
  • High sensitivity (as sensitive as or more sensitive than ELISA)
  • High reproducibility (CV < 10%)
  • Various sample types can be analyzed
    • Blood serum or plasma
    • Tissue
    • Cell culture
    • Cerebrospinal fluid (CSF)

 

Service Features

  • Study design
  • Protein extraction and purification
  • Protein quantification
  • Protein labelling with high-performance fluorescent dyes
  • Automated array incubation and handling 
  • Array scanning and data acquisition
  • Data analysis according to your requirements
  • Customized study report

 

Overview
Scio-Discover
    Biomarker
Discovery
    Contact
us

 

 

*Minimum quantity. These values may vary depending on the sample type, study design, storage conditions. and additional parameters.

** Antibody array is designed to target human proteins. Due to a high sequence homology of vast majority of proteins it was often successfully applied to study murine, rat and ovine models as well  [Thorenz A. et al. (2018), Peiro J. et al. (2018), Reichman H. et al. (2019), Raquel F. et al. (2020)].

*** Depending on study design and sample numbers.

 

Meet us

RExPO25—Barcelona (Sept 24–26, 2025)

We are thrilled to be part of RExPO25 in Barcelona (September 24–26)—the 4th International Conference on Systems Medicine, AI & Drug Repurposing. Meet us there and stay tuned for insights we’ll bring back!

BIO-Europe 2025—Vienna (Nov 3–5, 2025)

Meet us at BIO-Europe 2025 in Vienna—where partnerships in biopharma innovation begin.

News

Article | Lactate-driven immune hotspots resolved via SLC5A12 blockade

| August 2025 | Lactate signaling induces cytokine production and T/B cell clustering in Sjögren’s disease, and SLC5A12 blockade reverses these effects. Sciomics contributed to this study by comparing protein abundance and acetylation levels of murine cells using the scioDiscover protein profiling platform.

Certo, M, et al.. Lactate signalling leads to aggregation of immune-inflammatory hotspots and SLC5A12 blockade promotes their resolution. Nat Metab. 2025;7(8):1663-1680.  
Article | ECM stabilisation drives rapamycin‑mediated lifespan extension in Marfan mgR/mgR mice

| May 2025 | Rapamycin extends lifespan in a Marfan syndrome mouse model by stabilising the extracellular matrix via increased ECM protein expression. Sciomics supported this study by identifying differentially expressed proteins in rapamycin-treated mice using the scioDiscover microarray platform.

Zaradzki et al., Stabilisation of extracellular matrix is crucial to rapamycin-mediated life span increase in Marfan mgR/mgR mice. Biochem Pharmacol. 2025;235:116830  
Article | Exploration of Novel Biomarkers for Neurodegenerative Diseases

| December 2024 | Biomarker candidates for neurodegenerative diseases were identified by combining an exploratory proteomic approach with quantitative ligand-binding assays. Sciomics supported this study by proteomic screening of plasma and CSF samples of patients with different neurodegenerative diseases using the scioDiscover microarray platform.

Kenzelmann A, et al.. Exploration of Novel Biomarkers for Neurodegenerative Diseases Using Proteomic Analysis and Ligand-Binding Assays. Biomedicines. 2024;12(12):2794.  
Article | Altered Serum Proteins indicate Inflammation, Fibrogenesis and Angiogenesis in Fontan Patients

| September 2024 | Four identified serum proteins may advance diagnostic and therapeutic approaches by complementing traditional diagnostic laboratory variables. Sciomics contributed to this study by a scioCD serum analysis targeting different CD surface markers, cytokines and chemokines.

Michel M, Renaud D, Schmidt R, et al. Altered Serum Proteins Suggest Inflammation, Fibrogenesis and Angiogenesis in Adult Patients with a Fontan Circulation. International Journal of Molecular Sciences. 2024; 25(10):5416
 
Article | Vago-splenic signal transduction of cardioprotection in humans

| April 2024 | The spleen as a relay organ as well as the vagal innervation determine cardioprotective signal transduction of Remote Ischaemic Conditioning (RIC) and Auricular Tragus Stimulation (ATS). Sciomics contributed to this study by analysing plasma-dialysate samples using the scioDiscover microarray platform.

Lieder HR, Paket U, Skyschally A, et al. Vago-splenic signal transduction of cardioprotection in humans. Eur Heart J. 2024;45(34):3164-3177. 

Testimonials

PD Dr. med. Mascha O. Fiedler-Kalenka and Dr. med. Benjamin Seybold

Heidelberg University Hospital, Department of Anesthesiology, Heidelberg, GermanyGerman Center for Lung Research (DZL), Translational Lung Research Center Heidelberg (TLRC), Heidelberg, Germany

"From the very beginning, working with the friendly and highly competent team at Sciomics was both professional and refreshingly straightforward. We particularly valued their openness to our specific research questions and the expert support they provided in planning and interpreting our exploratory cytokine analysis in a preclinical lung injury model. Communication was always on equal footing, enriched by Sciomics’ deep expertise, which also sparked new ideas for future projects."

Product: scioCD

Tara Sigdel, PhD

Associate Professor, Department of Surgery, University of California San Francisco

"We collaborated with Sciomics GmbH in Germany to analyze proteomics data from blood samples of kidney transplant recipients and liver perfusates during normothermic machine perfusion. Throughout the process, Sciomics provided exceptional support, ensuring timely data delivery and valuable assistance with data analysis. Their expertise and commitment have been instrumental in advancing our research, and we are currently using their data in multiple manuscript submissions. I highly recommend Sciomics for their reliable service and expertise in proteomics."

Product: scioDiscover